Why do patients with chronic inflammatory rheumatic diseases discontinue their biologics? An assessment of patients' adherence using a self-report questionnaire

Journal of Rheumatology

Volumn 43, Issue 4, 2016, Pages 724-730

  Betegnie, Anne Laure ^a   Gauchet, Aurélie ^b   Lehmann, Audrey ^a   Grange, Laurent ^c   Roustit, Matthieu ^c   Baudrant, Magalie ^a,d   Bedouch, Pierrick ^a,d   Allenet, Benoît ^a,d  

^a University Hospital   (United States)

^b UNIVERSITÉ GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER   (France)

Author keywords

Adherence; Beliefs; Biologics; Discontinuation; Patient education; Rheumatic disease

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CHRONIC INFLAMMATORY RHEUMATIC DISEASE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PERCEPTION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SELF REPORT QUESTIONNAIRE; SIDE EFFECT; SOCIAL BELIEF; SOCIAL SUPPORT; VISUAL ANALOG SCALE; MIDDLE AGED; PSYCHOLOGY; SELF REPORT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SELF REPORT; SOCIAL SUPPORT; SPONDYLITIS, ANKYLOSING; SURVEYS AND QUESTIONNAIRES;

EID: 84982126135     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150414     Document Type: Article

References (38)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis [review]. Lancet 2007;370:1861-74.
2. Bingham CO 3rd. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008;66:210-5.
3. Krishnan E, Lingala B, Bruce B, Fries JF. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis 2012;71:213-8.
4. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
5. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: Results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002-8.
6. Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009;27:958-63.
7. Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, et al. Ten years with biologics: To whom do data on effectiveness and safety apply? Rheumatology 2011;50:204-13.
8. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MÁ, Carmona L; BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012;71:382-5.
9. Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: Results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013;72:1149-55.
10. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009;11:R52.
11. Duftner C, Dejaco C, Larcher H, Schirmer M, Herold M. Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic. Rheumatol Int 2008;29:69-73.
12. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-7.
13. Goldberg EL, Dekoven M, Schabert VF, Coyle A. Patient medication adherence: The forgotten aspect of biologics. Biotechnol Healthc 2009;6:39-44.
14. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010;10:1367-78.
15. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: A systematic review. Clin Ther 2011;33:901-13.
16. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
17. Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 2015;54:494-9.
18. Hughes D, Cowell W, Koncz T, Cramer J; International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498-509.
19. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77.
20. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 2008;59:1519-26.
21. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin M. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45 Suppl 2:S66-S76.
22. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9 Suppl:S136-43.
23. Betegnie AL, Lehmann A, Baudrant M, Roustit M, Bedouch P, Grange L, et al. [Adherence to biotherapy in inflammatory rheumatism: identifying ways to better support the patient]. [Article in French. Internet. Accessed January 13, 2016.] Available from: Www.freepaperdownload.us/1764/Article5569661.htm.
24. Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P, et al. Assessing medication adherence: options to consider. Int J Clin Pharm 2014;36:55-69.
25. Kline P. An easy guide to factor analysis. London: Routledge; 1994.
26. Cattell RB. The fallacy of five factors in the personality sphere. Psychologist 1995;8:207-8.
27. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74.
28. Régnier-Rosencher E, Farhi D, Lebrun A, Salliot C, Dougados M, Dupin N. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases. Dermatology 2012;224:72-83.
29. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119:3028-35.
30. Dobkin PL, Sita A, Sewitch MJ. Predictors of adherence to treatment in women with fibromyalgia. Clin J Pain 2006;22:286-94.
31. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
32. Brod M, Rousculp M, Cameron A. Understanding compliance issues for daily self-injectable treatment in ambulatory care settings. Patient Prefer Adherence 2008;2:129-36.
33. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008;27:883-9.
34. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
35. Westhoff G, Zink A. [Basic treatment of early rheumatoid arthritis. Abstaining from rheumatological care and preferring alternative medicine increase the risk of undertreatment]. [Article in German] Z Rheumatol 2007;66:121-4, 126-8.
36. Neame R, Hammond A, Deighton C. Need for information and for involvement in decision making among patients with rheumatoid arthritis: A questionnaire survey. Arthritis Rheum 2005;53:249-55.
37. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
38. Brus H, van de Laar M, Taal E, Rasker J, Wiegman O. Determinants of compliance with medication in patients with rheumatoid arthritis: The importance of self-efficacy expectations. Patient Educ Couns 1999;36:57-64.